Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.60 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784518 | 0.86 | PDCD1 (0.44) | PDCD1CD274DPP4ALDH1A1HSD17B10 | |
| SCHEMBL3785999 | 0.85 | ALDH1A1 (0.47) | PDCD1CD274DPP4ALDH1A1MAP4K4 | |
| SCHEMBL27762955 | 0.84 | DPP4 (0.48) | PDCD1CD274DPP4ALDH1A1HSD17B10 | |
| SCHEMBL3787555 | 0.83 | DPP4 (0.69) | PDCD1CD274DPP4ALDH1A1HSD17B10 | |
| SCHEMBL3786241 | 0.82 | ALDH1A1 (0.52) | PDCD1CD274DPP4ALDH1A1HSD17B10 | |
| SCHEMBL21665539 | 0.82 | DPP4 (0.50) | PDCD1CD274DPP4ALDH1A1HSD17B10 | |
| SCHEMBL11051064 | 0.81 | AKR1B1 (0.50) | PDCD1CD274DPP4KMT2AFOLH1 | |
| SCHEMBL27525656 | 0.80 | DPP4 (0.53) | PDCD1CD274DPP4ALDH1A1HSD17B10 | |
| SCHEMBL117091 | 0.80 | PDCD1 (0.65) | PDCD1CD274DPP4ALDH1A1HSD17B10 | |
| SCHEMBL30826353 | 0.80 | PDCD1 (0.65) | PDCD1CD274DPP4ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| EP-3765453-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112105610-A | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| CN-102348709-B | Material for organic electroluminescent device | MERCK PATENT GMBH | 2014-11-19 | — | — | CN | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| CN-1386118-A | Lactams substituted by cyclic succinates as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB CO (US) | 2002-12-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | CD274, PDCD1, PDCD1LG2 | PDCD1 2/4885CD274 1/4885DPP4 1292/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | PDCD1 465/4885CD274 1253/4885DPP4 3267/4885 |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | PDCD1 2/4885CD274 1/4885DPP4 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.